SENSEX NIFTY

Her2 Positive Breast Cancers

Jan 12, 2017 at 08:21 | Source: Moneycontrol.com
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylans biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.
Oct 12, 2015 at 19:41 | Source: PTI
These targeted medicines represent a completely new way to treat HER2-positive metastatic breast cancer, with which the company aims to help women in India live as long and as well as possible, he added.
Aug 19, 2015 at 17:36 | Source: PTI
These tests will help screen for cancer risks and enable families of cancer patients to take various preventive measures. All testing will be carried out at Myriad's labs in USA and Germany, the companies said in a statement.
Nov 26, 2013 at 14:42 | Source: Moneycontrol.com
Biocon has received marketing authorization from the Drugs Controller General of India for its Biosimilar Trastuzumab being developed jointly with Mylan, for treatment of Her 2+ metastatic breast cancer.

Photos »

  /  
USFDA to review Biocon-Mylan's biosimilar drug for breast cancer
Roche launches new breast cancer drugs in India
Myriad Genetics partners with Positive Bioscience
Biocon & Mylan receive Indian Regulatory approval for Biosimilar Trastuzumab
Follow us on
Available On